View Older Stories
-
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $37 at Goldman Sachs
-
Harmony Biosciences forecasts WAKIX revenue to exceed $1 billion in 2026
-
Beacon Biosignals partners with Harmony Biosciences for EEG sleep studies
-
Harmony Biosciences shows seizure reduction in dravet syndrome trial
-
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)
-
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $46 at Mizuho
-
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)
-
Harmony Biosciences reports positive pitolisant bioequivalence study results
-
Oppenheimer Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY) Post Mgmt Meet
-
Harmony Biosciences (HRMY) Tops Q3 EPS by 34c ; Offers Guidance
-
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)
-
Harmony Biosciences raises 2025 revenue guidance on strong WAKIX sales
-
Truist Securities: 'Is Biotech Back?!'
-
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $43 at UBS
-
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $55 at H.C. Wainwright
-
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $35 at Mizuho
-
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $62 at Oppenheimer
-
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $50 at Cantor Fitzgerald
-
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $50 at UBS Ahead of Topline Data
-
Harmony Biosciences (HRMY) 30-day option IV above 100
-
Harmony Biosciences (HRMY) call put ratio 3.7 calls to 1 put as share price down 5.6%
-
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $50 at Mizuho
-
Harmony Biosciences (HRMY) Tops Q2 EPS by 20c ; Offers Guidance
-
Truist Securities Starts Harmony Biosciences Holdings Inc. (HRMY) at Buy
-
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)
-
Goldman Sachs Resumes Harmony Biosciences Holdings Inc. (HRMY) at Neutral
-
Mizuho Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY)
-
Mizuho Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY)
-
Mizuho Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY)
-
Harmony Biosciences (HRMY) Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205
-
Harmony Biosciences (HRMY) Announces Favorable Settlement in ANDA Litigation
-
Oppenheimer Assumes Harmony Biosciences Holdings Inc. (HRMY) at Outperform
-
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $48 at Mizuho
-
Harmony Biosciences (HRMY) Tops Q1 EPS by 42c, provides guidance
-
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)
-
Oppenheimer on Harmony Biosciences (HRMY): 'we remain pleased with WAKIX's 4Q24 performance'
-
Harmony Biosciences (HRMY) Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome
-
Harmony Biosciences (HRMY) Appoints Ron Philip to its Board
-
Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald
-
Harmony Biosciences (HRMY) Appoints Adam Zaeske as Chief Commercial Officer
-
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $44 at Mizuho
-
Cantor Biotech industry report, buying value in RevGens
-
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $70 at H.C. Wainwright
-
Cantor Fitzgerald Reiterates Overweight Rating on Harmony Biosciences Holdings Inc. (HRMY)
-
Mizuho Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY)
-
Harmony Biosciences (HRMY) Tops Q4 EPS by 39c ; Offers Guidance
-
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)
-
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $42 at Mizuho
-
Harmony Biosciences (HRMY) Provides Update on the Status of the Supplemental New Drug Application for Pitolisant
-
Deutsche Bank Starts Harmony Biosciences Holdings Inc. (HRMY) at Buy

